In the current study, we used a tumor model that is known to be very sensitive to the MTD of cisplatin. Further studies in animal models with drug-resistant tumors are needed to explore the differences

in optical parameters in these settings. Moreover, it is likely that the changes in tumor tissue vary on the basis of the specific treatment given. To provide www.selleckchem.com/products/z-vad-fmk.html a more complete understanding of the relationship between optical spectroscopy parameters and pathologic response, the effect of other drugs on spectroscopy parameters needs to be investigated further. Conventional anatomic imaging alone lacks the sensitivity for early-response monitoring or assessing the effect of new targeted therapies that do not necessarily result in a change in tumor size. For these purposes, functional information, such as that obtained by 18F-FDG PET [7], [8] and [9] NU7441 clinical trial and contrast-enhanced magnetic resonance imaging [50] is more suitable. Optical spectroscopy is a relatively new functional imaging technique that may contribute to fast-response evaluation and timely shifting of systemic

treatment. This could be of great clinical benefit, even when it requires (minimal) invasive optical spectroscopy measurements in the tumor. In a time of personalized medicine, repeated tumor core biopsy is increasingly used during the course of treatment to generate a genetic or epigenetic profile allowing selection of the best possible treatment. Repeated biopsies may, however, be confounded by intratumor heterogeneity [51]. By performing optical spectroscopy along the needle path, an “optical tumor

profile” can be recorded covering a relatively large volume of tumor tissue. For example, Nachabe et al. [52] showed that optical spectroscopy measurements at the tip of a needle allowed real-time tissue characterization during percutaneous interventions. As such, optical spectroscopy offers the potential to measure real time alterations in the optical profile during systemic treatment. In this way, it may help to personalize cancer treatments SB-3CT and may improve cost effectiveness of systemic treatment in cancer. In summary, this study shows that dual-modality DRS–AFS provides quantitative functional information that corresponds well with the degree of pathologic response of systemic treatment. This could be of considerable value for the monitoring and prediction of cancer therapy efficacy on the basis of individual patient response. Further studies including resistant tumor models and various therapeutic drugs are needed to verify the initial findings of this work.